The role and strategy of ISoP in global pharmacovigilance
- 109 Downloads
Applying the WHO definition of pharmacovigilance, the International Society of Pharmacovigilance, (ISoP) is concerned with all aspects of medicine safety. The safety of patients exposed to medicines depends on a wide variety of factors, where the understanding of each factor is associated with its own professional competence and skillset. For pharmacovigilance systems to work efficiently, a broad understanding of the necessary contribution of each of the different scientific competence areas and professional skills is required. ISoP is an independent, not-for-profit international professional organization, concerned with the best interest of patients exposed to pharmaceutical interventions in all healthcare systems in the world. ISoP offers an open platform for professionals from around the world with different expertise and skillsets, to network and exchange information and knowledge in a friendly environment. The society wishes to become a stronger global voice, speaking up in favour of patient safety and to be at the frontline of the global patient safety movement.
KeywordsDrug safety International association Non-profit Patient safety Pharmacovigilance
Conflicts of interest
The authors declared that they have no conflict of interest.
- 2.Anonymous. The importance of Pharmacovigilance. Safety monitoring of medicinal products WHO 2002 http://apps.who.int/iris/bitstream/10665/42493/1/a75646.pdf. Accessed 11 Jan 2018.
- 3.www.isoponline.org. Accessed 11 Jan 2018.
- 4.Velo G. Ecopharmacovigilance. In: Edwards IR, Lindquist M, editors. Pharmacovigilance, critique and ways forward. Berlin: Springer; 2017. p. 195–205.Google Scholar
- 6.The International Society of Pharmacovigilance 18th Annual Meeting. http://www.isop2018geneva.org/. Accessed 18 July 2018.
- 8.Bahri P, Dodoo AN, Edwards BD, Edwards IR, Fermont I, Hagemann U, Hartigan-Go K, Hugman B, Mol PG. The ISoP CommSIG for improving medicinal product risk communication: a new special interest group of the International Society of Pharmacovigilance. Drug Saf. 2015;38:621–7 (on behalf of the ISoP CommSIG).CrossRefPubMedGoogle Scholar
- 9.Anonymous. WHO pharmaceuticals newsletter no 6, 2017, p. 22 http://www.who.int/medicines/publications/PharmaNewsletter6_17/en/. Accessed 11 Jan 2018.
- 11.Springer-Nature. Drug safety journal. https://www.springer.com/adis/journal/40264. Accessed 18 July 2018.